Clinical Trial Update: Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating adding inotuzumab ozogamicin to post-induction chemotherapy for high-risk acute lymphoblastic leukemia, mixed phenotype acute leukemi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Lymphoblastic Lymphoma
• Mixed Phenotype Acute Leukemia

Drugs mentioned

• Besponsa (inotuzumab ozogamicin) (Inotuzumab ozogamicin)

Snippet

Sponsor: Children's Oncology Group | Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma | Phase 3 | Status: RECRUITING